GGrantIndex
← Leaderboards

Stephen Tomlinson

Ralph H Johnson Va Medical Center

$13,528,891
Attributed
$15,258,182
Total exposure
22
Grants
18
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$15,258,182 · 15
VA$0 · 7

By mechanism

R01$10,048,911 · 8
U01$1,868,750 · 1
T32$1,216,508 · 1
R56$1,155,037 · 3
R21$968,976 · 2
I01$0 · 4

Top collaborators

Most similar at Ralph H Johnson Va Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Complement

Research focus

ComplementComplement ActivationInflammationInjuryComplement InactivatorsClinically RelevantPlayLinkComplement SystemSiteInflammatoryBaseActivation ProductComplement PathwayEventPathway InteractionsMouse ModelReperfusion InjuryResponseAffectMediatingAcuteImmunoglobulin MCells

Grant awards (82)

The role of complement in chronic neuroinflammation and cognitive decline after closed head brain injury$0
I01 · FY2025 · VA · contact PI
The complement system in ALS$0
I21 · FY2024 · VA · contact PI
BLR&D Research Career Scientist Award Application for Dr. Stephen Tomlinson$0
IK6 · FY2024 · VA · contact PI
Role of complement in TBI$0
I01 · FY2024 · VA · contact PI
The role of complement in chronic neuroinflammation and cognitive decline after closed head brain injury$0
I01 · FY2024 · VA · contact PI
Role of complement in TBI$0
I01 · FY2023 · VA · contact PI
The role of complement in chronic neuroinflammation and cognitive decline after closed head brain injury$0
I01 · FY2023 · VA · contact PI
BLR&D Research Career Scientist Award Application for Dr. Stephen Tomlinson$0
IK6 · FY2023 · VA · contact PI
The complement system in ALS$0
I21 · FY2023 · VA · contact PI
Cell survival in engineered skeletal muscle: The role of complement$405,831
R01 · FY2022 · EB · contact PI
Impact of Comorbidities on Stroke Outcomes and Treatments$0
I01 · FY2022 · VA · contact PI
BLR&D Research Career Scientist Award Application for Dr. Stephen Tomlinson$0
IK6 · FY2022 · VA · contact PI
Impact of Comorbidities on Stroke Outcomes and Treatments$0
I01 · FY2022 · VA · contact PI
Role of complement in TBI$0
I01 · FY2022 · VA · contact PI
Cell survival in engineered skeletal muscle: The role of complement$397,714
R01 · FY2021 · EB
Graft-targeted anti-complement therapy to reduce cardiac graft injury and allograft vasculopathy$373,750
U01 · FY2021 · AI · contact PI
Brain death associated vascularized composite allograft injury and its impact on alloimmunity and functional recovery$337,831
R56 · FY2021 · AI
Program in Immunology Research and Entrepreneurship (PIRE)$269,076
T32 · FY2021 · AI · contact PI
Brain death associated vascularized composite allograft injury and its impact on alloimmunity and functional recovery$74,706
R56 · FY2021 · AI
BLR&D Research Career Scientist Award Application for Dr. Stephen Tomlinson$0
IK6 · FY2021 · VA · contact PI
Role of complement in TBI$0
I01 · FY2021 · VA · contact PI
Cell survival in engineered skeletal muscle: The role of complement$405,831
R01 · FY2020 · EB
Graft-targeted anti-complement therapy to reduce cardiac graft injury and allograft vasculopathy$373,750
U01 · FY2020 · AI · contact PI
Program in Immunology Research and Entrepreneurship (PIRE)$291,793
T32 · FY2020 · AI · contact PI
Role of complement in TBI$0
I01 · FY2020 · VA · contact PI
Impact of Comorbidities on Stroke Outcomes and Treatments$0
I01 · FY2020 · VA · contact PI
BLR&D Research Career Scientist Award Application for Dr. Stephen Tomlinson$0
IK6 · FY2020 · VA · contact PI
Impact of Comorbidities on Stroke Outcomes and Treatments$0
I01 · FY2020 · VA · contact PI
Graft-targeted anti-complement therapy to reduce cardiac graft injury and allograft vasculopathy$373,750
U01 · FY2019 · AI · contact PI
Program in Immunology Research and Entrepreneurship (PIRE)$266,639
T32 · FY2019 · AI · contact PI
Impact of Comorbidities on Stroke Outcomes and Treatments$0
I01 · FY2019 · VA · contact PI
Role of complement in TBI$0
I01 · FY2019 · VA · contact PI
Graft-targeted anti-complement therapy to reduce cardiac graft injury and allograft vasculopathy$373,750
U01 · FY2018 · AI · contact PI
Complement inhibitors targeted to the ischemic brain for the treatment of stroke$360,856
R21 · FY2018 · NS · contact PI
Antibodies and complement in ischemia reperfusion injury and regeneration$329,852
R01 · FY2018 · DK · contact PI
Program in Immunology Research and Entrepreneurship (PIRE)$261,244
T32 · FY2018 · AI · contact PI
Targeting complement and chronic inflammation after traumatic brain injury$0
I21 · FY2018 · VA · contact PI
Antibodies and complement in ischemia reperfusion injury and regeneration$454,192
R01 · FY2017 · DK · contact PI
Graft-targeted anti-complement therapy to reduce cardiac graft injury and allograft vasculopathy$373,750
U01 · FY2017 · AI · contact PI
Complement inhibitors targeted to the ischemic brain for the treatment of stroke$345,320
R21 · FY2017 · NS · contact PI
Program in Immunology Research and Entrepreneurship (PIRE)$127,756
T32 · FY2017 · AI · contact PI
Novel Therapies to Improve Functional Recovery After Stroke$0
I01 · FY2017 · VA · contact PI
Antibodies and complement in ischemia reperfusion injury and regeneration$454,192
R01 · FY2016 · DK · contact PI
Complement, anti-tumor immunity and apoptosis-based therapy$306,063
R01 · FY2016 · CA · contact PI
Targeting complement and chronic inflammation after traumatic brain injury$0
I21 · FY2016 · VA · contact PI
Novel Therapies to Improve Functional Recovery After Stroke$0
I01 · FY2016 · VA · contact PI
Antibodies and complement in ischemia reperfusion injury and regeneration$466,565
R01 · FY2015 · DK · contact PI
Immune sensing of ischemic injury and complement-dependent modulation of alloimmunity in cardiac transplantation$373,750
R56 · FY2015 · AI · contact PI
Complement, anti-tumor immunity and apoptosis-based therapy$306,063
R01 · FY2015 · CA · contact PI
Novel Therapies to Improve Functional Recovery After Stroke$0
I01 · FY2015 · VA · contact PI
The Complement System and Spinal Cord Injury$0
I01 · FY2015 · VA · contact PI
Complement, anti-tumor immunity and apoptosis-based therapy$296,881
R01 · FY2014 · CA · contact PI
The Complement System and Spinal Cord Injury$0
I01 · FY2014 · VA · contact PI
Novel Therapies to Improve Functional Recovery After Stroke$0
I01 · FY2014 · VA · contact PI
Complement, anti-tumor immunity and apoptosis-based therapy$287,699
R01 · FY2013 · CA · contact PI
The Complement System and Spinal Cord Injury$0
I01 · FY2013 · VA · contact PI
Dual role of complement in post-ischemic inflammation and recovery$368,750
R56 · FY2012 · AI · contact PI
Complement, anti-tumor immunity and apoptosis-based therapy$306,063
R01 · FY2012 · CA · contact PI
The Complement System and Spinal Cord Injury$0
I01 · FY2012 · VA · contact PI
Role of complement in brain death induced injury to donor hearts$374,334
R01 · FY2010 · HL · contact PI
Controlling complement in cerebral ischemic injury$318,974
R01 · FY2010 · HL · contact PI
Role of complement in brain death induced injury to donor hearts$373,974
R01 · FY2009 · HL · contact PI
Controlling complement in cerebral ischemic injury$318,974
R01 · FY2009 · HL · contact PI
Role of complement in brain death induced injury to donor hearts$373,630
R01 · FY2008 · HL · contact PI
Controlling complement in cerebral ischemic injury$318,974
R01 · FY2008 · HL · contact PI
Role of complement in brain death induced injury to donor hearts$384,797
R01 · FY2007 · HL · contact PI
Controlling complement in cerebral ischemic injury$318,974
R01 · FY2007 · HL · contact PI
Controlling complement in cerebral ischemic injury$328,500
R01 · FY2006 · HL · contact PI
Interaction Between CD59 and Its Complement Ligands$264,267
R01 · FY2006 · AI · contact PI
Complement inhibitors and immunotherapy$131,400
R21 · FY2005 · CA
Interaction Between CD59 and Its Complement Ligands$1
R01 · FY2005 · AI
Interaction Between CD59 and Its Complement Ligands$270,591
R01 · FY2004 · AI
Complement inhibitors and immunotherapy$131,400
R21 · FY2004 · CA
TARGETED COMPLEMENT INHIBITORS$321,750
R01 · FY2003 · AI
Interaction Between CD59 and Its Complement Ligands$270,555
R01 · FY2003 · AI
TARGETED COMPLEMENT INHIBITORS$289,575
R01 · FY2002 · AI
Interaction Between CD59 and Its Complement Ligands$270,520
R01 · FY2002 · AI
Interaction Between CD59 and Its Complement Ligands$264,929
R01 · FY2001 · AI
TARGETED COMPLEMENT INHIBITORS$214,500
R01 · FY2001 · AI
TARGETED COMPLEMENT INHIBITORS$214,500
R01 · FY2000 · AI
LYSIS OF TRYPANOSOMA BRUCEI BY HUMAN SERUM$98,784
R01 · FY2000 · AI
LYSIS OF TRYPANOSOMA BRUCEI BY HUMAN SERUM$40,862
R01 · FY2000 · AI